MannKind Corporation to Hold 2022 First Quarter Financial Results Conference Call on May 5, 2022
April 28 2022 - 6:00AM
MannKind Corporation (Nasdaq: MNKD) will release
its 2022 first quarter financial results and its management will
host a conference call to discuss the financial results and
corporate updates at 5:00 PM (Eastern Time) on Thursday, May 5,
2022.
Presenting from the Company will be its Chief Executive Officer,
Michael Castagna and Chief Financial Officer, Steven Binder.
Those interested in listening to the conference call live via
the Internet may do so by visiting the Company's website at
https://mannkindcorp.com/news-events/ under Events.
About MannKind CorporationMannKind Corporation
(Nasdaq: MNKD) focuses on the development and commercialization of
inhaled therapeutic products for patients with endocrine and orphan
lung diseases. MannKind is currently commercializing Afrezza®
(insulin human) Inhalation Powder, the Company’s first FDA-approved
product and the only inhaled ultra rapid-acting mealtime insulin in
the United States, where it is available by prescription from
pharmacies nationwide. Afrezza is also available by prescription in
Brazil, where it is commercialized by the Company’s partner, Biomm
SA. MannKind was established in 1991, and is located in Danbury,
Conn., and Westlake Village, Calif. The Company also employs field
sales and medical representatives across the U.S. Please visit
mannkindcorp.com to learn more.
For MannKind: Rose Alinaya,
Investor Relations(818) 661-5000Email: ir@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Aug 2024 to Sep 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Sep 2023 to Sep 2024